ClinicalTrials.gov
public full text
Public Domain
A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma
The goal of the Phase I portion of this study is to find the highest tolerable dose of TPI 287 that can be given in combination with Temodar (temozolomide) to patients with metastatic melanoma. The goal of the Phase II portion of this study is to learn if TPI 287, given in combination with temozolomide, can control metastatic melanoma. The safety of this combination will also be studied. NOTE: Study stopped before progressing to Phase II portion.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Open-Label Study of TPI 287 for Patients With Metastatic Melanoma#812406
- A Phase 1 of CTX-8371 in Patients With Advanced Malignancies#804246
- Combined Modality Treatment for Patients With Stage IV Melanoma#835971
- Intratumoral PH-762 for Cutaneous Carcinoma#803309
- Combinatii (Betametazona 0.5 Mg + Gentamicina 1 Mg) Unguent - Tub#139567
Record · ID 855149
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive